董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tomer Berkovitz | 男 | Director | 42 | 未披露 | 未持股 | 2022-02-01 |
| Troy Cox | 男 | Chairman of the Board | 57 | 未披露 | 未持股 | 2022-02-01 |
| Kathy Hibbs | 女 | Director | 58 | 未披露 | 未持股 | 2022-02-01 |
| Vincent Ossipow | 男 | Director | 53 | 未披露 | 未持股 | 2022-02-01 |
| Milton Silva Craig | 男 | Director | 54 | 未披露 | 未持股 | 2022-02-01 |
| Jurgi Camblong | 男 | Chief Executive Officer and Director | 43 | 未披露 | 未持股 | 2022-02-01 |
| Didier Hirsch | 男 | Director | 70 | 未披露 | 未持股 | 2022-02-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jurgi Camblong | 男 | Chief Executive Officer and Director | 43 | 未披露 | 未持股 | 2022-02-01 |
| Ross Muken | 男 | Chief Financial Officer | 42 | 未披露 | 未持股 | 2022-02-01 |
| Daan van Well | 男 | Chief Legal Officer | 47 | 未披露 | 未持股 | 2022-02-01 |
| Manuela da Silva Valente | 女 | Chief People Officer | 52 | 未披露 | 未持股 | 2022-02-01 |
| Zhenyu Xu | -- | Chief Scientific Officer | 39 | 未披露 | 未持股 | 2022-02-01 |
| Philippe Menu | -- | Chief Medical Officer | 40 | 未披露 | 未持股 | 2022-02-01 |
董事简历
中英对照 | 中文 | 英文- Tomer Berkovitz
-
Tomer Berkovitz于2014年5月加入Alcobra并担任财务总监。在加入Alcobra之前，从2008年起担任纽约（New York）J.P. Morgan投资银行业务部的执行董事，担任许多资本市场和并购交易的重要领导职位。在这些职位上，他曾为J.P. Morgan主要美国客户的高级管理曾和董事会提供了建议，这些公司包括S&P500医疗公司。加入J.P. Morgan前，曾在纽约（New York）Citigroup的投资银行工作。2000-2003年，曾是以色列国防军参谋长财务顾问部门的经济学家。持有Columbia商学院的财务和经济学博士学位，曾在一些主要的学术和从业杂志上发表许多公司财务文章。还持有Tel-Aviv大学的财务和会计硕士学位，以及经济和管理学学士学位。
Tomer Berkovitz, has served as a member of our board of directors since March 2021. Since 2018 Dr. Berkovitz has served as General Partner of aMoon Fund, where he co-leads its Growth fund. From 2014 to 2018 Dr. Berkovitz served as the Chief Operating Officer and Chief Financial Officer of Alcobra Ltd. Prior to that, Mr. Berkovitz served as an Executive Director in J.P. Morgan's investment banking division in New York. In addition to our board of directors, Dr. Berkovitz serves on the board of directors of several other healthcare companies in the aMoon portfolio. Dr. Berkovitz holds a Ph.D. in finance from Columbia Business School. - Tomer Berkovitz于2014年5月加入Alcobra并担任财务总监。在加入Alcobra之前，从2008年起担任纽约（New York）J.P. Morgan投资银行业务部的执行董事，担任许多资本市场和并购交易的重要领导职位。在这些职位上，他曾为J.P. Morgan主要美国客户的高级管理曾和董事会提供了建议，这些公司包括S&P500医疗公司。加入J.P. Morgan前，曾在纽约（New York）Citigroup的投资银行工作。2000-2003年，曾是以色列国防军参谋长财务顾问部门的经济学家。持有Columbia商学院的财务和经济学博士学位，曾在一些主要的学术和从业杂志上发表许多公司财务文章。还持有Tel-Aviv大学的财务和会计硕士学位，以及经济和管理学学士学位。
- Tomer Berkovitz, has served as a member of our board of directors since March 2021. Since 2018 Dr. Berkovitz has served as General Partner of aMoon Fund, where he co-leads its Growth fund. From 2014 to 2018 Dr. Berkovitz served as the Chief Operating Officer and Chief Financial Officer of Alcobra Ltd. Prior to that, Mr. Berkovitz served as an Executive Director in J.P. Morgan's investment banking division in New York. In addition to our board of directors, Dr. Berkovitz serves on the board of directors of several other healthcare companies in the aMoon portfolio. Dr. Berkovitz holds a Ph.D. in finance from Columbia Business School.
- Troy Cox
-
Troy Cox自2017年2月起担任我们的首席执行官兼董事会成员，并于2017年12月任命考克斯先生担任额外的总裁职位，该职位于2018年2月生效。考克斯先生从2010年2月至2017年2月从Genentech，Inc.基因技术公司（Genentech”；）加入我们，担任高级副总裁，生物肿瘤学销售和营销职位。在加入Genentech之前，Cox先生担任UCB S.A.（“；UCB Biopharma”；）的CNS运营总裁，负责开发和商业化主要与中枢神经系统相关的疾病的疗法。在加入UCB Biopharma之前，Cox先生在Sanofi-Aventis和Schering-Plough担任高级商业领导职务。Cox先生在肯塔基大学（University of Kentucky）获得金融学学士学位，并在密苏里大学（University of Missouri）获得工商管理硕士学位。
Troy Cox, has served as the Chairman of our board of directors since June 2019. From 2017 to 2019 Mr. Cox served as the chief executive officer of Foundation Medicine Inc. From 2010 to 2017 Mr. Cox served as the senior vice president of U.S. commercial of Genentech, Inc. Prior to that, Mr. Cox held various executive and senior positions at UCB S.A., Sanofi-Aventis U.S. LLC and Schering-Plough Corporation. In addition to our board of directors, Mr. Cox serves on the board of directors of Massachusetts Biotechnology Council, Zymeworks Inc., LetsGetChecked, Somalogic Inc., BioSplice Therapeutics, Inc. and previously served on the board of directors of Foundation Medicine Inc. Mr. Cox holds an M.B.A. from the University of Missouri. - Troy Cox自2017年2月起担任我们的首席执行官兼董事会成员，并于2017年12月任命考克斯先生担任额外的总裁职位，该职位于2018年2月生效。考克斯先生从2010年2月至2017年2月从Genentech，Inc.基因技术公司（Genentech”；）加入我们，担任高级副总裁，生物肿瘤学销售和营销职位。在加入Genentech之前，Cox先生担任UCB S.A.（“；UCB Biopharma”；）的CNS运营总裁，负责开发和商业化主要与中枢神经系统相关的疾病的疗法。在加入UCB Biopharma之前，Cox先生在Sanofi-Aventis和Schering-Plough担任高级商业领导职务。Cox先生在肯塔基大学（University of Kentucky）获得金融学学士学位，并在密苏里大学（University of Missouri）获得工商管理硕士学位。
- Troy Cox, has served as the Chairman of our board of directors since June 2019. From 2017 to 2019 Mr. Cox served as the chief executive officer of Foundation Medicine Inc. From 2010 to 2017 Mr. Cox served as the senior vice president of U.S. commercial of Genentech, Inc. Prior to that, Mr. Cox held various executive and senior positions at UCB S.A., Sanofi-Aventis U.S. LLC and Schering-Plough Corporation. In addition to our board of directors, Mr. Cox serves on the board of directors of Massachusetts Biotechnology Council, Zymeworks Inc., LetsGetChecked, Somalogic Inc., BioSplice Therapeutics, Inc. and previously served on the board of directors of Foundation Medicine Inc. Mr. Cox holds an M.B.A. from the University of Missouri.
- Kathy Hibbs
-
Kathy Hibbs自2021年3月起担任我们的董事会成员。自2014年以来，Hibbs女士一直担任23andMe，Inc.的首席法律和监管官。在此之前，Hibbs女士在GenomicHealth，Inc.，Monogram Biosciences Inc.和瓦里安医疗系统公司担任法律，业务开发和合规职能的多种领导职务Hibbs女士此前曾任职Decipher Biosciences，Inc.董事会。Hibbs女士拥有加州大学黑斯廷斯法学院法学博士学位。
Kathy Hibbs,is 23andme Holding Co. Chief Administrative Officer and Secretary. She previously served as 23andme Holding Co. Chief Legal and Regulatory Officer and Secretary from June 2021 to February 2022 and as the Chief Legal and Regulatory Officer of 23andMe, Inc. from 2014 to June 2021. Previously, Ms. Hibbs served as Senior Vice President and General Counsel of Genomic Health, Inc., a genetic research and cancer diagnostics company, from 2009 to 2014. Prior to that, from 2000 to 2009, Ms. Hibbs served as Senior Vice President and General Counsel of Monogram Biosciences Inc., and from 1995 to 1999, she was the Director of Legal Affairs at Varian Associates, Inc. followed by its successor, Varian Medical Systems, Inc. Ms. Hibbs served on the board of directors of Decipher Biosciences, Inc. (Nasdaq: DECI) until its acquisition. She also serves as a member of the Fast Company Impact Council and as a member of the board of directors of Cadex Genomics, Corp., a private company focused on molecular diagnostics tests to guide cancer treatment, and the board of directors of Sophia Genetics, a private Al platform company whose products are 23andme Holding Co. ed by more than 1,000 healthcare institutions. Ms. Hibbs also currently serves as the Chair of the Compensation Committee of Sophia Genetics. Ms. Hibbs received her B.A. in Political Science from the University of California, Riverside, and her J.D. from the University of California, Hastings College of the Law. - Kathy Hibbs自2021年3月起担任我们的董事会成员。自2014年以来，Hibbs女士一直担任23andMe，Inc.的首席法律和监管官。在此之前，Hibbs女士在GenomicHealth，Inc.，Monogram Biosciences Inc.和瓦里安医疗系统公司担任法律，业务开发和合规职能的多种领导职务Hibbs女士此前曾任职Decipher Biosciences，Inc.董事会。Hibbs女士拥有加州大学黑斯廷斯法学院法学博士学位。
- Kathy Hibbs,is 23andme Holding Co. Chief Administrative Officer and Secretary. She previously served as 23andme Holding Co. Chief Legal and Regulatory Officer and Secretary from June 2021 to February 2022 and as the Chief Legal and Regulatory Officer of 23andMe, Inc. from 2014 to June 2021. Previously, Ms. Hibbs served as Senior Vice President and General Counsel of Genomic Health, Inc., a genetic research and cancer diagnostics company, from 2009 to 2014. Prior to that, from 2000 to 2009, Ms. Hibbs served as Senior Vice President and General Counsel of Monogram Biosciences Inc., and from 1995 to 1999, she was the Director of Legal Affairs at Varian Associates, Inc. followed by its successor, Varian Medical Systems, Inc. Ms. Hibbs served on the board of directors of Decipher Biosciences, Inc. (Nasdaq: DECI) until its acquisition. She also serves as a member of the Fast Company Impact Council and as a member of the board of directors of Cadex Genomics, Corp., a private company focused on molecular diagnostics tests to guide cancer treatment, and the board of directors of Sophia Genetics, a private Al platform company whose products are 23andme Holding Co. ed by more than 1,000 healthcare institutions. Ms. Hibbs also currently serves as the Chair of the Compensation Committee of Sophia Genetics. Ms. Hibbs received her B.A. in Political Science from the University of California, Riverside, and her J.D. from the University of California, Hastings College of the Law.
- Vincent Ossipow
-
Vincent Ossipow自2014年6月起担任董事会成员。Ossipow博士一直是欧米茄基金的合伙人。Ossipow博士自2021年1月起还担任Omega Alpha SPAC的首席科学官。在此之前，Ossipow博士曾在部门资产管理公司和Pictet Bank担任多个投资管理职位。除了我们的董事会，Ossipow博士还任职于Immunic，Inc.，BioInvent International AB，Forx SA和Etherna Immunotherapies NV的董事会，此前曾任职于Andrew Alliance S.A.，Lifespan，Inc.，Raindance Technologies，CNX SA和Kuros Biosciences AG的董事会。Ossipow博士拥有日内瓦大学分子生物学博士学位。
Vincent Ossipow, has served as a member of our board of directors since June 2014. Dr. Ossipow has been a partner at Omega Funds. Dr. Ossipow has also served as the Chief Scientific Officer of Omega Alpha SPAC. Prior to that, Dr. Ossipow held various investment management positions at Sectoral Asset Management and Pictet Bank. In addition to our board of directors, Dr. Ossipow serves on the board of directors of Immunic, Inc., BioInvent International AB, FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. Dr. Ossipow holds a Ph.D. in molecular biology from the University of Geneva. - Vincent Ossipow自2014年6月起担任董事会成员。Ossipow博士一直是欧米茄基金的合伙人。Ossipow博士自2021年1月起还担任Omega Alpha SPAC的首席科学官。在此之前，Ossipow博士曾在部门资产管理公司和Pictet Bank担任多个投资管理职位。除了我们的董事会，Ossipow博士还任职于Immunic，Inc.，BioInvent International AB，Forx SA和Etherna Immunotherapies NV的董事会，此前曾任职于Andrew Alliance S.A.，Lifespan，Inc.，Raindance Technologies，CNX SA和Kuros Biosciences AG的董事会。Ossipow博士拥有日内瓦大学分子生物学博士学位。
- Vincent Ossipow, has served as a member of our board of directors since June 2014. Dr. Ossipow has been a partner at Omega Funds. Dr. Ossipow has also served as the Chief Scientific Officer of Omega Alpha SPAC. Prior to that, Dr. Ossipow held various investment management positions at Sectoral Asset Management and Pictet Bank. In addition to our board of directors, Dr. Ossipow serves on the board of directors of Immunic, Inc., BioInvent International AB, FoRx SA, SwissThera SA, and eTheRNA immunotherapies NV, and previously served on the board of directors of Andrew Alliance S.A., Lifespan, Inc., Raindance Technologies, CNx SA and Kuros Biosciences AG. Dr. Ossipow holds a Ph.D. in molecular biology from the University of Geneva.
- Milton Silva Craig
-
Milton Silva Craig自2019年11月起担任董事会成员。自2014年起，Silva-Craig先生担任Q-Centrix，LLC的首席执行官。在此之前，Silva-Craig先生在TransUnion LLC，Technology Solutions Company，Emageon Inc和General Electric医疗保健担任执行职务。除了我们的董事会，Silva-Craig先生还在Q-Centrix，LLC的董事会任职，此前曾在Healthmyne，Inc.的董事会任职。Silva-Craig先生拥有威斯康星大学麦迪逊分校的法学博士和工商管理硕士学位。
Milton Silva Craig, has served as a member of our board of directors since November 2019. Since 2014 Mr. Silva-Craig has served as the Chief Executive Officer of Q-Centrix, LLC. Prior to that, Mr. Silva-Craig held executive positions at TransUnion LLC, Technology Solutions Company, Emageon Inc and General Electric Healthcare. In addition to our board of directors, Mr. Silva-Craig serves on the board of directors for Q-Centrix, LLC and previously served on the board of directors of HealthMyne, Inc. Mr. Silva-Craig holds a J.D. and M.B.A. from the University of Wisconsin - Madison. - Milton Silva Craig自2019年11月起担任董事会成员。自2014年起，Silva-Craig先生担任Q-Centrix，LLC的首席执行官。在此之前，Silva-Craig先生在TransUnion LLC，Technology Solutions Company，Emageon Inc和General Electric医疗保健担任执行职务。除了我们的董事会，Silva-Craig先生还在Q-Centrix，LLC的董事会任职，此前曾在Healthmyne，Inc.的董事会任职。Silva-Craig先生拥有威斯康星大学麦迪逊分校的法学博士和工商管理硕士学位。
- Milton Silva Craig, has served as a member of our board of directors since November 2019. Since 2014 Mr. Silva-Craig has served as the Chief Executive Officer of Q-Centrix, LLC. Prior to that, Mr. Silva-Craig held executive positions at TransUnion LLC, Technology Solutions Company, Emageon Inc and General Electric Healthcare. In addition to our board of directors, Mr. Silva-Craig serves on the board of directors for Q-Centrix, LLC and previously served on the board of directors of HealthMyne, Inc. Mr. Silva-Craig holds a J.D. and M.B.A. from the University of Wisconsin - Madison.
- Jurgi Camblong
-
Jurgi Camblong自2011年3月以来一直担任我们的首席执行官和董事会成员，当时他与Pierre Hutter博士和Lars Steinmetz教授共同创立了我们的公司。从2010年到2011年，Camblong博士担任Gene Predictis SA的首席执行官。在此之前，Camblong博士是牛津大学和日内瓦大学的博士后副研究员。Camblong博士是瑞士政府数字转型咨询委员会的成员，也是瑞士生物技术协会的董事会成员。Camblong博士拥有日内瓦大学生命科学博士学位和EPFL/HEC Lausanne技术管理高级工商管理硕士学位。
Jurgi Camblong, has served as our Chief Executive Officer and a member of our board of directors since March 2011 when he co-founded our company with Dr. Pierre Hutter and Professor Lars Steinmetz. From 2010 to 2011 Dr. Camblong served as the Chief Executive Officer of Gene Predictis SA. Prior to that, Dr. Camblong was a post-doctoral associate researcher at Oxford University and at the University of Geneva. Dr. Camblong was a member of the Advisory Council on Digital Transformation to the Swiss Government and is a Board member of the Swiss Biotech Association. In addition to our board of directors, Dr. Camblong serves as Chair of the Board of AgoraCare SA. Dr. Camblong holds a Ph.D. in life sciences from the University of Geneva and an Executive M.B.A. in management of technology from EPFL/HEC Lausanne. - Jurgi Camblong自2011年3月以来一直担任我们的首席执行官和董事会成员，当时他与Pierre Hutter博士和Lars Steinmetz教授共同创立了我们的公司。从2010年到2011年，Camblong博士担任Gene Predictis SA的首席执行官。在此之前，Camblong博士是牛津大学和日内瓦大学的博士后副研究员。Camblong博士是瑞士政府数字转型咨询委员会的成员，也是瑞士生物技术协会的董事会成员。Camblong博士拥有日内瓦大学生命科学博士学位和EPFL/HEC Lausanne技术管理高级工商管理硕士学位。
- Jurgi Camblong, has served as our Chief Executive Officer and a member of our board of directors since March 2011 when he co-founded our company with Dr. Pierre Hutter and Professor Lars Steinmetz. From 2010 to 2011 Dr. Camblong served as the Chief Executive Officer of Gene Predictis SA. Prior to that, Dr. Camblong was a post-doctoral associate researcher at Oxford University and at the University of Geneva. Dr. Camblong was a member of the Advisory Council on Digital Transformation to the Swiss Government and is a Board member of the Swiss Biotech Association. In addition to our board of directors, Dr. Camblong serves as Chair of the Board of AgoraCare SA. Dr. Camblong holds a Ph.D. in life sciences from the University of Geneva and an Executive M.B.A. in management of technology from EPFL/HEC Lausanne.
- Didier Hirsch
-
Didier Hirsch，自2020年6月起担任Sophia Genetics董事会成员。2010年至2018年，Hirsch先生担任Agilent Technologies, Inc.高级副总裁兼首席财务官。在此之前，Hirsch先生曾在Agilent Technologies, Inc.和Hewlett-Packard Company担任多个财务领导职务。除了Sophia Genetics董事会成员外，Hirsch先生还在Knowles公司董事会任职，之前还曾在Logitech International S.A.和国际整流器公司董事会任职。Hirsch先生拥有图卢兹大学计算机科学硕士学位和普渡大学工业管理硕士学位。
Didier Hirsch, has served as a member of Sophia Genetics Sa board of directors since June 2020. From 2010 to 2018 Mr. Hirsch served as the senior vice president and chief financial officer of Agilent Technologies, Inc. Prior to that, Mr. Hirsch held various leadership roles in finance at Agilent Technologies, Inc. and Hewlett-Packard Company. In addition to Sophia Genetics Sa board of directors, Mr. Hirsch serves on the board of directors of Knowles Corporation and previously served on the board of directors of Logitech International S.A. and International Rectifier Corporation. Mr. Hirsch holds an M.Sc. in computer science from Toulouse University and an M.S. in industrial administration from Purdue University. - Didier Hirsch，自2020年6月起担任Sophia Genetics董事会成员。2010年至2018年，Hirsch先生担任Agilent Technologies, Inc.高级副总裁兼首席财务官。在此之前，Hirsch先生曾在Agilent Technologies, Inc.和Hewlett-Packard Company担任多个财务领导职务。除了Sophia Genetics董事会成员外，Hirsch先生还在Knowles公司董事会任职，之前还曾在Logitech International S.A.和国际整流器公司董事会任职。Hirsch先生拥有图卢兹大学计算机科学硕士学位和普渡大学工业管理硕士学位。
- Didier Hirsch, has served as a member of Sophia Genetics Sa board of directors since June 2020. From 2010 to 2018 Mr. Hirsch served as the senior vice president and chief financial officer of Agilent Technologies, Inc. Prior to that, Mr. Hirsch held various leadership roles in finance at Agilent Technologies, Inc. and Hewlett-Packard Company. In addition to Sophia Genetics Sa board of directors, Mr. Hirsch serves on the board of directors of Knowles Corporation and previously served on the board of directors of Logitech International S.A. and International Rectifier Corporation. Mr. Hirsch holds an M.Sc. in computer science from Toulouse University and an M.S. in industrial administration from Purdue University.
高管简历
中英对照 | 中文 | 英文- Jurgi Camblong
Jurgi Camblong自2011年3月以来一直担任我们的首席执行官和董事会成员，当时他与Pierre Hutter博士和Lars Steinmetz教授共同创立了我们的公司。从2010年到2011年，Camblong博士担任Gene Predictis SA的首席执行官。在此之前，Camblong博士是牛津大学和日内瓦大学的博士后副研究员。Camblong博士是瑞士政府数字转型咨询委员会的成员，也是瑞士生物技术协会的董事会成员。Camblong博士拥有日内瓦大学生命科学博士学位和EPFL/HEC Lausanne技术管理高级工商管理硕士学位。
Jurgi Camblong, has served as our Chief Executive Officer and a member of our board of directors since March 2011 when he co-founded our company with Dr. Pierre Hutter and Professor Lars Steinmetz. From 2010 to 2011 Dr. Camblong served as the Chief Executive Officer of Gene Predictis SA. Prior to that, Dr. Camblong was a post-doctoral associate researcher at Oxford University and at the University of Geneva. Dr. Camblong was a member of the Advisory Council on Digital Transformation to the Swiss Government and is a Board member of the Swiss Biotech Association. In addition to our board of directors, Dr. Camblong serves as Chair of the Board of AgoraCare SA. Dr. Camblong holds a Ph.D. in life sciences from the University of Geneva and an Executive M.B.A. in management of technology from EPFL/HEC Lausanne.- Jurgi Camblong自2011年3月以来一直担任我们的首席执行官和董事会成员，当时他与Pierre Hutter博士和Lars Steinmetz教授共同创立了我们的公司。从2010年到2011年，Camblong博士担任Gene Predictis SA的首席执行官。在此之前，Camblong博士是牛津大学和日内瓦大学的博士后副研究员。Camblong博士是瑞士政府数字转型咨询委员会的成员，也是瑞士生物技术协会的董事会成员。Camblong博士拥有日内瓦大学生命科学博士学位和EPFL/HEC Lausanne技术管理高级工商管理硕士学位。
- Jurgi Camblong, has served as our Chief Executive Officer and a member of our board of directors since March 2011 when he co-founded our company with Dr. Pierre Hutter and Professor Lars Steinmetz. From 2010 to 2011 Dr. Camblong served as the Chief Executive Officer of Gene Predictis SA. Prior to that, Dr. Camblong was a post-doctoral associate researcher at Oxford University and at the University of Geneva. Dr. Camblong was a member of the Advisory Council on Digital Transformation to the Swiss Government and is a Board member of the Swiss Biotech Association. In addition to our board of directors, Dr. Camblong serves as Chair of the Board of AgoraCare SA. Dr. Camblong holds a Ph.D. in life sciences from the University of Geneva and an Executive M.B.A. in management of technology from EPFL/HEC Lausanne.
- Ross Muken
Ross Muken自2021年2月起担任公司首席财务官。从2019年到2020年，Muken先生担任Click Therapeutics，Inc.的首席财务官。从2012年到2019年，Muken先生担任Evercore/ISI Group的高级董事总经理兼股票研究合伙人。在此之前，Muken先生在德意志银行（Deutsche Bank）和Thomas Weisel Partners担任各种职务，包括股票研究董事总经理。Muken先生拥有学士学位。波士顿大学工商管理专业。
Ross Muken, has served as our Chief Financial Officer since February 2021. From 2019 to 2020 Mr. Muken served as the Chief Financial Officer of Click Therapeutics, Inc. From 2012 to 2019 Mr. Muken served as the Senior Managing Director and Partner of Equity Research at Evercore/ISI Group. Prior to that, Mr. Muken served in various roles at Deutsche Bank, including as Managing Director of Equity Research, and at Thomas Weisel Partners. Mr. Muken holds a B.Sc. in business administration from Boston University.- Ross Muken自2021年2月起担任公司首席财务官。从2019年到2020年，Muken先生担任Click Therapeutics，Inc.的首席财务官。从2012年到2019年，Muken先生担任Evercore/ISI Group的高级董事总经理兼股票研究合伙人。在此之前，Muken先生在德意志银行（Deutsche Bank）和Thomas Weisel Partners担任各种职务，包括股票研究董事总经理。Muken先生拥有学士学位。波士顿大学工商管理专业。
- Ross Muken, has served as our Chief Financial Officer since February 2021. From 2019 to 2020 Mr. Muken served as the Chief Financial Officer of Click Therapeutics, Inc. From 2012 to 2019 Mr. Muken served as the Senior Managing Director and Partner of Equity Research at Evercore/ISI Group. Prior to that, Mr. Muken served in various roles at Deutsche Bank, including as Managing Director of Equity Research, and at Thomas Weisel Partners. Mr. Muken holds a B.Sc. in business administration from Boston University.
- Daan van Well
Daan Van Well自2019年6月起担任我们的首席法务官。Van Well先生拥有超过20年的法律、治理和合规经验。从2018年到2019年，Van Well先生担任咨询公司Springworks Sà；RL的创始人兼管理合伙人。从2010年到2017年，Van Well先生在瑞士普华永道担任多个法律职位，包括从2011年到2017年担任法律主管。在此之前，Van Well先生担任Royal Ahold N.V.（目前为Koninklijke Ahold Delhaize N.V.）的公司秘书和高级法律顾问，并在荷兰鹿特丹的Loyens&Loeff N.V.执业。Van Well先生持有法学硕士学位。乌得勒支大学（Utrecht University）的荷兰民法硕士学位，以及洛桑高等商学院（HEC Lausanne）的管理和企业融资高级MBA学位。Van Well先生是荷兰精酿啤酒公司Gran Fondo B.V.的联合创始人和股东，该公司将Abloc啤酒商业化。
Daan van Well, has served as our Chief Legal Officer since June 2019. Mr. Van Well has more than 20 years of legal, governance and compliance experience. From 2018 to 2019 Mr. Van Well served as the founder and managing partner of consulting firm SpringWorks Sàrl. From 2010 to 2017 Mr. Van Well served in various legal positions with PwC Switzerland, including as the Head of Legal from 2011 to 2017. Prior to that, Mr. Van Well served as corporate secretary and senior legal counsel of Royal Ahold N.V. currently Koninklijke Ahold Delhaize N.V. and practiced law at Loyens & Loeff N.V. in Rotterdam, The Netherlands. Mr. Van Well holds a LL.M. in Dutch civil law from Utrecht University and an Executive M.B.A. in management and corporate finance from HEC Lausanne.- Daan Van Well自2019年6月起担任我们的首席法务官。Van Well先生拥有超过20年的法律、治理和合规经验。从2018年到2019年，Van Well先生担任咨询公司Springworks Sà；RL的创始人兼管理合伙人。从2010年到2017年，Van Well先生在瑞士普华永道担任多个法律职位，包括从2011年到2017年担任法律主管。在此之前，Van Well先生担任Royal Ahold N.V.（目前为Koninklijke Ahold Delhaize N.V.）的公司秘书和高级法律顾问，并在荷兰鹿特丹的Loyens&Loeff N.V.执业。Van Well先生持有法学硕士学位。乌得勒支大学（Utrecht University）的荷兰民法硕士学位，以及洛桑高等商学院（HEC Lausanne）的管理和企业融资高级MBA学位。Van Well先生是荷兰精酿啤酒公司Gran Fondo B.V.的联合创始人和股东，该公司将Abloc啤酒商业化。
- Daan van Well, has served as our Chief Legal Officer since June 2019. Mr. Van Well has more than 20 years of legal, governance and compliance experience. From 2018 to 2019 Mr. Van Well served as the founder and managing partner of consulting firm SpringWorks Sàrl. From 2010 to 2017 Mr. Van Well served in various legal positions with PwC Switzerland, including as the Head of Legal from 2011 to 2017. Prior to that, Mr. Van Well served as corporate secretary and senior legal counsel of Royal Ahold N.V. currently Koninklijke Ahold Delhaize N.V. and practiced law at Loyens & Loeff N.V. in Rotterdam, The Netherlands. Mr. Van Well holds a LL.M. in Dutch civil law from Utrecht University and an Executive M.B.A. in management and corporate finance from HEC Lausanne.
- Manuela da Silva Valente
Manuela da Silva Valente自2019年1月起担任我们的首席人事官。da Silva Valente女士拥有超过20年的人力资源经验。2011年至2018年，da Silva Valente女士曾在IQVIA（前昆泰和IMS HealthInc.）担任各种人力资源领导职务，包括2016年至2018年担任全球人力资源高级总监。在此之前，da Silva Valente女士在Outcome Sciences，Inc.被IQVIA收购之前担任过各种人力资源职务。da Silva Valente女士拥有苏黎世商业管理学院的工商管理学士学位和洛桑CEFCO的管理与人力资源文凭。
Manuela da Silva Valente, has served as our Chief People Officer since January 2019. Ms. Da Silva Valente has more than 20 years of human resources experience. From 2011 to 2018 Ms. Da Silva Valente served in various human resources leadership roles at IQVIA formerly Quintiles and IMS Health Inc., including as Global Senior Director of Human Resources from 2016 to 2018. Prior to that, Ms. Da Silva Valente held various human resources roles at Outcome Sciences, Inc. prior to its acquisition by IQVIA. Ms. Da Silva Valente holds a B.A. in business administration from the Business Management School of Zurich and a Management & Human Resources Diploma from CEFCO Lausanne.- Manuela da Silva Valente自2019年1月起担任我们的首席人事官。da Silva Valente女士拥有超过20年的人力资源经验。2011年至2018年，da Silva Valente女士曾在IQVIA（前昆泰和IMS HealthInc.）担任各种人力资源领导职务，包括2016年至2018年担任全球人力资源高级总监。在此之前，da Silva Valente女士在Outcome Sciences，Inc.被IQVIA收购之前担任过各种人力资源职务。da Silva Valente女士拥有苏黎世商业管理学院的工商管理学士学位和洛桑CEFCO的管理与人力资源文凭。
- Manuela da Silva Valente, has served as our Chief People Officer since January 2019. Ms. Da Silva Valente has more than 20 years of human resources experience. From 2011 to 2018 Ms. Da Silva Valente served in various human resources leadership roles at IQVIA formerly Quintiles and IMS Health Inc., including as Global Senior Director of Human Resources from 2016 to 2018. Prior to that, Ms. Da Silva Valente held various human resources roles at Outcome Sciences, Inc. prior to its acquisition by IQVIA. Ms. Da Silva Valente holds a B.A. in business administration from the Business Management School of Zurich and a Management & Human Resources Diploma from CEFCO Lausanne.
- Zhenyu Xu
徐振宇自2021年1月起担任我们的首席科学官，此前自2014年5月起担任我们的首席技术官。Xu博士是开发我们的Sophia平台的技术团队的负责人。在此之前，徐博士是欧洲分子生物学实验室的博士后研究员。Xu博士拥有欧洲分子生物学实验室的分子和计算生物学博士学位。
Zhenyu Xu, has served as our Chief Scientific Officer since January 2021 and was previously our Chief Technology Officer since May 2014. Dr. Xu was the leader of the technology team that developed our SOPHiA platform. Prior to that, Dr. Xu was a post-doctoral fellow at the European Molecular Biology Laboratory. Dr. Xu holds a Ph.D. in molecular and computational biology from the European Molecular Biology Laboratory.- 徐振宇自2021年1月起担任我们的首席科学官，此前自2014年5月起担任我们的首席技术官。Xu博士是开发我们的Sophia平台的技术团队的负责人。在此之前，徐博士是欧洲分子生物学实验室的博士后研究员。Xu博士拥有欧洲分子生物学实验室的分子和计算生物学博士学位。
- Zhenyu Xu, has served as our Chief Scientific Officer since January 2021 and was previously our Chief Technology Officer since May 2014. Dr. Xu was the leader of the technology team that developed our SOPHiA platform. Prior to that, Dr. Xu was a post-doctoral fellow at the European Molecular Biology Laboratory. Dr. Xu holds a Ph.D. in molecular and computational biology from the European Molecular Biology Laboratory.
- Philippe Menu
Philippe Menu自2020年2月起担任我们的首席医疗官。从2011年到2020年，Menu博士是麦肯锡公司的管理顾问，专注于生物制药行业，尤其是肿瘤和罕见疾病的创新疗法和诊断。在此之前，Menu博士是洛桑大学的博士后研究员。Menu博士拥有洛桑大学生命科学的M.D./Ph.D.和开放大学商学院的M.B.A.。
Philippe Menu, has served as our Chief Medical Officer since February 2020. From 2011 to 2020 Dr. Menu was a management consultant with McKinsey & Company, focusing on the biopharmaceutical sector and in particular innovative therapies and diagnostics in oncology and rare diseases. Prior to that, Dr. Menu was a post-doctoral fellow at the University of Lausanne. Dr. Menu holds an M.D./Ph.D. in life sciences from the University of Lausanne and an M.B.A. from the Open University Business School.- Philippe Menu自2020年2月起担任我们的首席医疗官。从2011年到2020年，Menu博士是麦肯锡公司的管理顾问，专注于生物制药行业，尤其是肿瘤和罕见疾病的创新疗法和诊断。在此之前，Menu博士是洛桑大学的博士后研究员。Menu博士拥有洛桑大学生命科学的M.D./Ph.D.和开放大学商学院的M.B.A.。
- Philippe Menu, has served as our Chief Medical Officer since February 2020. From 2011 to 2020 Dr. Menu was a management consultant with McKinsey & Company, focusing on the biopharmaceutical sector and in particular innovative therapies and diagnostics in oncology and rare diseases. Prior to that, Dr. Menu was a post-doctoral fellow at the University of Lausanne. Dr. Menu holds an M.D./Ph.D. in life sciences from the University of Lausanne and an M.B.A. from the Open University Business School.